Raise closed, search for fresh raises on Seedstage

Lumberton, MS

Advancing therapies to relieve oral pain in cancer and dental care patients.

• Innovative Therapy: Triamdocaine dry powder spray for severe oral mucositis pain relief.
• FDA-Approved Trials: IND approval secured; Phase 2 clinical trials currently underway.
• Dual Market Focus: Targeting unmet needs in both oncology and dental care sectors.
• Long-Term Patent Protection: Intellectual property secured through 2039.
• Social Impact Mission: Cancer Comfort Care Initiative prioritizes patient quality of life.
• Growth Market: Positioned in two expanding healthcare sectors with significant unmet need.
• Experienced Leadership: Led by a team with extensive healthcare and business expertise.

RAM Pharmaceuticals is raising funds to advance its innovative therapies that provide relief for patients suffering from oral pain due to cancer treatments and dental conditions. The primary focus is on Triamdocaine, a novel dry powder spray designed to alleviate the pain of severe oral mucositis (SOM), a common side effect of chemotherapy and radiation. The funds will support ongoing clinical trials, regulatory milestones, and expanded manufacturing to accelerate the availability of this groundbreaking treatment. With FDA Investigational New Drug (IND) approval secured and Phase 2 trials underway, RAM Pharmaceuticals is positioned to make a significant impact in supportive oncology care.

Beyond cancer care, the company is also developing Acyclonine MUM, a therapy targeting various oral health conditions like mucosal ulcerations, post-operative pain, and traumatic injuries. By addressing both oncology and dental markets, RAM Pharmaceuticals is tapping into high-growth sectors driven by increasing cancer diagnoses and the rising demand for advanced dental care. With patents extending through 2039, a compassionate mission to restore dignity and comfort, and a robust clinical strategy, the company aims to become a leader in supportive care for oral health.

Company Info

RAM Pharmaceuticals develops therapies like Triamdocaine to relieve oral mucositis pain in cancer patients and Acyclonine MUM for dental conditions.

RAM Pharmaceuticals is a clinical-stage company focused on improving the quality of life for cancer patients and individuals with oral health challenges through innovative therapies. Its flagship product, Triamdocaine, is a dry powder spray designed to provide rapid, localized relief from severe oral mucositis (SOM)—a common, painful side effect of cancer treatments. Triamdocaine combines anesthetic, antiviral, and anti-inflammatory agents to help patients speak, eat, and connect with loved ones during their cancer journey.

In addition to oncology, RAM Pharmaceuticals addresses dental health with Acyclonine MUM, a proven therapy for oral conditions like mucosal ulcerations, post-operative pain, and traumatic injuries. With FDA IND approval for Triamdocaine, patents secured through 2039, and a presence in two high-growth healthcare sectors, RAM Pharmaceuticals is positioned to redefine supportive care for cancer patients and expand its impact within the dental care industry.